CM
AVXL icon

Caption Management’s Anavex Life Sciences AVXL Stock Holding History

Caption Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-354,838
Closed -$1.26M – 1558
2025
Q4 		$1.26M Buy
+354,838
New +$2.17M 0.01% 979
2021
Q3 		– Sell
-73,000
Closed -$1.45M – 1502
2021
Q2 		$1.67M Buy
+73,000
New +$1.08M 0.02% 747

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caption Management's AVXL Position: Q1 2026 in Review

Caption Management sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 354,838 shares — an estimated $1.26M sold.

Caption Management first reported a position in AVXL in Q2 2021 and held it in 2 quarters. The position peaked at $1.67M in Q2 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Caption Management reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 354,838 Anavex Life Sciences shares in Q1 2026, an estimated $1.26M.
  • Caption Management first reported a position in Anavex Life Sciences in Q2 2021 and held it in 2 quarters.
  • Caption Management's Anavex Life Sciences position peaked at $1.67M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.